Autonomic dysreflexia (AD), a potentially dangerous complication of high-level spinal cord injury (SCI) characterized by exaggerated activation of spinal autonomic (sympathetic) reflexes, can cause pulmonary embolism, stroke, and, in severe cases, death. People with high-level SCI also are immune compromised, rendering them more susceptible to infectious morbidity and mortality. The mechanisms underlying postinjury immune suppression are not known. Data presented herein indicate that AD causes immune suppression. Using in vivo telemetry, we show that AD develops spontaneously in SCI mice with the frequency of dysreflexic episodes increasing as a function of time postinjury. As the frequency of AD increases, there is a corresponding increase in splenic leukopenia and immune suppression. Experimental activation of spinal sympathetic reflexes in SCI mice (e.g., via colorectal distension) elicits AD and exacerbates immune suppression via a mechanism that involves aberrant accumulation of norepinephrine and glucocorticoids. Reversal of postinjury immune suppression in SCI mice can be achieved by pharmacological inhibition of receptors for norepinephrine and glucocorticoids during the onset and progression of AD. In a human subject with C5 SCI, stimulating the micturition reflex caused AD with exaggerated catecholamine release and impaired immune function, thus confirming the relevance of the mouse data. These data implicate AD as a cause of secondary immune deficiency after SCI and reveal novel therapeutic targets for overcoming infectious complications that arise due to deficits in immune function.

Introduction

Infections impair neurological recovery and increase morbidity and mortality after spinal cord injury (SCI), stroke, and traumatic brain injury (Meisel et al., 2005; Failli et al., 2012). Infectious complications are prevalent in these patient populations and are likely caused by a poorly defined complication referred to as CNS injury-induced immune deficiency syndrome (CIDS; Meisel et al., 2005). The mechanistic basis for CIDS was studied here in the context of SCI.

The hypothalamic-pituitary-adrenal axis and sympathetic nervous system are key regulators of immune function (Irwin and Cole, 2011). In response to psychological or physical stress, hypothalamic neurons release corticotropin-releasing hormone

into the anterior pituitary, which in turn releases adrenocorticotropic hormone into the bloodstream. Adrenocorticotropic hormone subsequently stimulates release of glucocorticoids (GCs) from the adrenal cortex.

Activation of spinal sympathetic preganglionic neurons (SPNs) causes release of norepinephrine (NE) and GCs from postganglionic nerve terminals and the adrenal gland (Engelland and Arnhold, 2005). SPNs are the source of all sympathetic outflow from the spinal cord (Elenkov et al., 2000). Visceral and somatic afferents activate SPNs, which send cholinergic projections to postganglionic neurons that innervate target organs including blood vessels, lymphoid tissues (e.g., spleen), and the adrenal medulla. SPNs also innervate the adrenal cortex directly, providing a rapid and direct mechanism for enhancing GC release (Engelland and Arnhold, 2005). Physiological concentrations of GCs and NE ensure normal immune function but recurrent or prolonged activation of glucocorticoid receptors (GRs) or β-2 adrenergic receptors (β2ARs) is immunosuppressive (Nance and Sanders, 2007). Therefore, sustained or uncontrolled activation of the sympathetic nervous system will prolong release of GCs and NE and could promote immune suppression.

Injury to the upper thoracic (above T6) or cervical spinal cord removes SPNs from supraspinal control, eliciting in particular constriction of the splanchnic vasculature. When this happens, common somatic or visceral stimuli (e.g., bladder or bowel dis-
tension) can elicit autonomic dysreflexia (AD), a life-threatening complication of high-level SCI characterized by excessive activation of SPNs with severe episodic hypertension (Inskipp et al., 2009). Because the spinal autonomic circuitry that triggers AD also controls immune function, we investigated here whether the onset or progression of AD was associated with chronic secondary immune deficiency (i.e., CIDDS).

We report that AD develops spontaneously in mice with high-level SCI and is associated with aberrant accumulation of circulating GCs and intrasplenic NE. As the frequency of spontaneous AD increases, the magnitude of splenic atrophy, splenocyte apoptosis, and immune suppression also increase. The experimental induction of AD in mice (e.g., colorectal distension) potently suppresses immune function. Moreover, selective βAR and GR antagonists restore immune function in chronic SCI mice. The clinical relevance of these experimental data was confirmed in a single human subject with C5 SCI. Eliciting a micturition reflex in this subject caused AD with reflexive release of excess catecholamines and immune suppression. These data indicate that a similar approach could be used to alleviate CIDDS and reduce infectious morbidity and mortality after SCI in human subjects.

Materials and Methods

Animals and SCI. Adult pathogen-free C57BL/6 female mice (10–11 weeks old; The Jackson Laboratory) were maintained in a pathogen-free environment. After acclimating mice to the laboratory environment (~7 d), mice were randomized into different experimental groups. Before surgery, mice were anesthetized intraperitoneally with a mixture of ketamine (80 mg/kg) and xylazine (40 mg/kg) and then complete spinal cord transection injuries were performed as described previously (Lucin et al., 2007). Briefly, using aseptic technique, a partial laminectomy was performed at vertebral level T3 or T9, after which the periosteum and dura mater were carefully opened. Using iridectomy scissors together with gentle aspiration, the spinal cord was cut, creating a clear separation between the rostral and caudal stumps of transected spinal cord. Complete transections were confirmed visually by gently lifting the rostral and caudal stumps within the spinal canal using a blunt probe. After injury, muscle and skin were sutured separately and then mice were injected with sterile saline (2 mL, s.c.) and placed individually into warmed HEPA-filtered cages. Sham-injured animals received a laminectomy at T3 but no SCI. Postoperative care included manual bladder expression 2×/d and daily antibiotics for the first 7 d post injury (dpi) (gentocin, 5 mg/kg, s.c.). Dehydration was monitored daily and body weight and urinary pH were monitored weekly. All procedures were approved by the Institutional Laboratory Animal Care and Use Committee at The Ohio State University.

Surgical implantation of telemetry transmitters. The PhysioTel telemetry system with PA-C10 telemetry transmitters (Data Sciences International) was used to quantify cardiovascular changes in sham-injured and SCI mice. PA-C10 transmitters are implantable, eliminating the need for catheter maintenance. Transmitters were prepared as per manufacturer instructions and then implanted in anesthetized mice 3 d before SCI via venous catheterization at vertebral level T9 (Lucin et al., 2007). Under aseptic technique and body temperature maintained for 1 min and repeat stimulation occurred after a 30 min rest. Peak changes in BP and corresponding HR were obtained and then compared with baseline values.

Ovalbumin immunizations and ELISA analysis. At 18 dpi, mice were injected intraperitoneally with 100 µg of ovalbumin (OVA; Sigma) emulsified in an equal volume of TiterMax Gold adjuvant (Sigma). Serum anti-OVA IgG1 concentrations were determined 10 d later (28 dpi) using ELISA. ELISA 96-well plates were coated with 100 µg/ml OVA diluted in PBS/0.02% sodium azide. After incubating overnight at 4°C, plates were washed and then blocked (37°C, 2 h) with PBS/1% BSA (Sigma). After another round of washing (PBS/0.05% Tween 20), serum samples or standards were pipetted into each well (20 µl/well) with overnight incubation at 4°C. Standard curves were prepared on each plate. Finally, plates were washed and then alkaline phosphatase-conjugated goat anti-mouse IgG (Southern Biotechnology Associates) diluted 1:1000 in PBS/1% BSA (37°C, 2 h) was applied. Bound antibodies were visualized by incubating with 1 mg/ml p-nitrophenyl phosphate (Sigma). Spectrophotometric readings were performed at 405 nm (Spectramax kinetic microplate reader; Molecular Devices).
designed to automatically detect spontaneously occurring events of AD in the HR/BP data. The semiautomated procedure for screening raw data to detect spontaneous AD consisted of three steps. First, establish baselines (green lines) for clipped BP and raw HR data using lowess and robust lowess smoothing filters. Filters were applied in consecutive 6 min epochs (smoothing window). A 6 min window was empirically determined to be optimal (compared with 2, 4, 8, or 10 min; data not shown). Second, simultaneously compare BP and HR data to baseline values. For the computer to automatically register an “event,” BP change from baseline (H1) must exceed 10 mmHg and persist above baseline for >30 s (T1). During T1, HR must decrease at least 10 bpm below baseline (H2). To register a simultaneous change in HR and BP as a “dysreflexic event,” the duration of the BP increase (T1) and HR decrease (T2) must overlap for at least 66% of the measured interval. Third, export BP/HR traces in which suspected AD events occur, and then visually confirm the event (see H3, T3, and H4). Real spontaneous AD events with H3 > 20 mmHg, T3 > 30 s, and H4 > 10 BPM are documented in B. This final manual confirmation eliminates detection of false-positive events reported by the algorithm. B. The number of daily bouts of spontaneous AD increases in T3 SCI mice in two phases: a transient increase during the first week postinjury (Phase I), followed by a gradual but consistent increase in the total number of daily events after 14 dpi (Phase II). **p < 0.01; ***p < 0.001 compared with T3 Sham or T9 SCI. C. High-frequency spontaneous AD in T3 SCI mice is associated with a full urinary bladder. Immediately before morning bladder expression, the number of spontaneous dysreflexic events is higher than after bladder expression. Data show individual data points (and group means) for sequentially collected spontaneous AD events from 0 to 2 h before and 1 to 3 h after morning bladder expression in a subset of mice at 26, 27, and 28 dpi. n = 5–6/group; **p < 0.01.

were monitored using a small animal monitoring system (model 1025; Small Animals Instruments). A pneumatic pillow was used to monitor respiration. Core temperature was maintained using a warm water bath. Imaging was performed using a Bruker Biospin 94/30 magnet and a 3.5-cm-diameter volume coil. Data were collected using a FLASH sequence (TR = 180–250 ms, TE = 2.3 ms, flip angle = 55°; numerical aperture = 10) with the following acquisition parameters: FOV = 22 mm × 22 mm, slice thickness = 0.5 mm, matrix size = 256 × 256. Slices were obtained as a short axis of spleen. For data analysis, a region-of-interest that included spleen was manually outlined. Spleen volumes were calculated from the outlined region-of-interest.

Serum collection. Whole blood was obtained from awake, unrestrained mice via submandibular bleeds. Samples were collected at 10:00 to 11:00 A.M. the day before surgery (baseline) and then at the designated days postinjury. When bled, mice were handled for <30 s and then returned to “recovery” cages. Animals were housed singly in recovery cages and isolated from the area in which mice were being bled. After recovery, mice were group housed as before. Blood was centrifuged and serum transferred into sterile tubes, which were frozen and stored at −80°C until use.

RIA analysis of corticosterone. Serum samples were assayed for total corticosterone (CORT) concentration using a double antibody 125I radioimmunoassay kit (MP Biomedicals) according to the manufacturer’s instructions and counted on a gamma counter (Packard Instrument). CORT levels were determined in duplicate from a standard curve and expressed in nanograms per milliliter. The minimum detectable limit for this assay was 5 ng/ml.

HPLC quantification of catecholamines. Spleens were quickly removed and then placed in liquid nitrogen to halt degradation of catecholamines. All isolated tissues were stored at −80°C until the time of extraction. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines. Tissue was weighed then quickly homogenized in 1 ml of 0.2 N acetic acid homogenization buffer (1 ml of glacial acetic acid, 26.9 μl of 0.5 M EDTA, 0.5 ml of 0.5 M MgCl₂, 250 μl of 0.5 M KCl, and 1 ml of 1 M NaCl) and then placed in liquid nitrogen to halt degradation of catecholamines.
Figure 3. Progressive splenic atrophy and leukopenia occur only after T3 SCI in mice with high-frequency spontaneous AD. A, Serial in vivo MRI scans (inverted using Photoshop) from a single mouse illustrate the progressive splenic atrophy that occurs after T3 SCI. Top: Two-dimensional view of thoracic cavity highlighting the location and relative size of the spleen at 0, 7, 21, and 35 dpi (arrow). Bottom: Three-dimensional reconstructions of that spleen illustrate the magnitude of splenic atrophy. B, Serial measures of spleen volume calculated from MRI images at 0, 7, 21, and 35 dpi for each T3 SCI mouse (open circles) then normalized to 0 dpi. n = 4; *p < 0.05 compared with 0, 7, or 21 dpi; closed symbols represent group mean over time. C, Spleen weight is significantly reduced at 35 dpi only in T3 SCI mice.

Statistics. Data are presented as mean ± SEM for groups and all analyses were performed using GraphPad Prism version 5.0 software. Comparisons between two group means were made using a two-tailed Student’s t test. Three or more group means were compared using one-way ANOVA with Tukey’s post hoc test. Two-way ANOVA with Bonferroni’s post tests were used to compare datasets containing two factors: for example, frequency of spontaneous AD and time or mean arterial BP (MABP)/HR and time. Group differences were considered statistically significant at p < 0.05.

Results
AD develops spontaneously in mice after high-level SCI
A primary goal was to study the interrelationship between naturally occurring (spontaneous) AD and progressive changes in systemic immune function. Usually, to study AD, scientists measure HR and BP changes elicited by a visceral-sympathetic reflex (e.g., colorectal distension) in SCI rats or mice instrumented with

PBS and stored for 48–72 h. Sucrose-infiltrated tissues were embedded in optimal cutting temperature medium (Sakura Finetek) and then rapidly frozen at −80°C. Serial coronal cryosections (10 μm) of spleen were cut and mounted onto SuperFrostPlus slides (Fisher Scientific). Immunohistochemical stains were performed using antibodies specific for CD45R/B220 (clone RA3-6B2; AbD Serotec), CD3 (clone 17A2; BD Biosciences), and cleaved Caspase-3 (clone AP835; R&D Systems). Alexa Fluor 488/546/633 secondary antibodies were used to visualize bound primary antibodies. The relative density of splenic B cells was determined by quantifying the area of CD45R/B220 double-stained cellular profiles within a standardized region of interest in three equidistant sections. Image capture and quantification was performed using an MCID Elite Turnkey system. Final fluorescent images were imported into Adobe Photoshop CS3 and a “levels” adjustment layer was applied to reveal the full tonal range of visible pixels in the RGB histogram.

Flow cytometry. Splenocyte subsets were analyzed using a FACSCanto II flow cytometer with FACSDiva software (BD Biosciences). Briefly, spleens were removed and then bisected. Weights of both halves were acquired and then single cell suspensions were made from half the spleen. Viable splenocytes were counted on a hemacytometer and then 1 × 10⁶ cells were incubated with Fc-block (anti-mouse-CD16/CD32; BD Biosciences) before incubating with directly conjugated antibodies. All samples were stained with the following antibodies: anti-B220-FITC (BD Biosciences), anti-CD23-PE (BD Biosciences), anti-IgM-PerCP-Cy5.5 (BD Biosciences), anti-AA4.1-APC (eBioscience), anti-CD21/35-eFluor450 (eBioscience), anti-CD4-FITC (BD Biosciences), anti-CD8-PE (BD Biosciences), anti-CD11b-V450 (BD Biosciences), and viability-eFluor780 (eBioscience). At least 10,000 events were collected per sample. Data presented in Figure 4 were derived from the percentage of labeled cells in splenocyte suspensions multiplied by the total splenocyte count. Offline data analyses were completed with FlowJo software (TreeStar).

0.1 g sodium bisulfite in 99 ml of ddH₂O) using glass microhomogenizers. Samples were centrifuged at 700 × g for 5 min. Supernatant catecholamines were extracted by the standard acidified alumina technique with a catecholamine extraction kit (ESA Biosciences) and performed according to the manufacturer’s instructions. An extra 100 μl of supernatant was kept for the BSA protein assay. Quantitative analysis of catecholamines was determined by HPLC using a Waters system mobile phase and electrochemical detector. 3,4-Dihydroxybenzylamine was used as an internal standard for calculation by HPLC using a Waters system mobile phase and electrochemical detector.
arterial cannulae. Because of the inherent difficulties in maintaining patent cannulae, this type of preparation typically lasts only a few days. For our purposes, rather than repeatedly remove and insert new cannulae to measure cardiovascular changes, an approach that would undoubtedly cause stress and immune suppression, we adapted an *in vivo* telemetry technique to detect and quantify daily spontaneous changes in HR and BP in unrestrained sham-injured or SCI mice for up to 5 consecutive weeks (Mayorov et al., 2001; Inskip et al., 2009; Rabchevsky et al., 2012).

A semiautomated custom computer algorithm also was designed to detect bouts of episodic hypertension with concurrent bradycardia (i.e., AD) from raw HR/BP telemetry traces (Fig. 1A). Using this approach, spontaneous AD was detected in T3 but not T9 SCI mice (Fig. 1B). AD develops within 5 to 10 dpi and is reminiscent of early onset AD described in tetraplegics (Krassioukov et al., 2003). A second phase of AD develops after 14 dpi with the number of episodes increasing ~10-fold between 2 and 5 weeks postinjury reaching a maximum of 25–30 epi-

**Figure 4.** Numbers of all splenic leukocyte subsets are reduced after high-level SCI. Suspensions of splenic leukocytes were phenotyped using specific antibodies. A representative flow cytometry scatter plot of splenic leukocytes (side scatter/SSC vs forward scatter/FSC) and leukocyte-specific histograms is shown to illustrate the approach for quantifying B lymphocytes (B220+), CD4+, or CD8+ T lymphocytes, macrophages (MΦ, CD11b+) or dendritic cells (DCs, CD11c+). Bar graphs show mean cell numbers at 21 or 35 dpi after T3 SCI, T9 SCI, or T3 Lam. Data are presented as mean cell numbers ± SEM (× 10⁶). Isotype control antibodies were used to set cursors in histogram plots. Only half a spleen was used for flow cytometry. n = 5/group; *p < 0.05; **p < 0.01; ***p < 0.001.
sodes/d. In people with high-level SCI, a full bladder often elicits AD (Curt et al., 1997). A similar viscerosympathetic reflex appears to be a natural periodic stimulus for AD in SCI mice, because the frequency of spontaneous AD was significantly reduced 1–3 h after morning bladder expression (Fig. 1).

Progression of AD predicts chronic immune suppression after SCI

We showed previously that excess GCs and NE kill leukocytes (Lucin et al., 2007; Lucin et al., 2009). Because recurrent activation of SPNs during bouts of AD should cause GCs and NE to accumulate in the circulation and spleen, we predicted that AD-induced changes in GCs/NE would correlate with the development of post-SCI immune suppression. In support of this hypothesis, we found that blood CORT (endogenous GC in mice) and splenic NE levels increased significantly 15–35 dpi after T3 SCI, when the frequency of spontaneous AD increased 2-fold (Fig. 2). Circulating CORT and splenic NE also were elevated after T9 SCI; however, significant differences were not evident until 28 dpi and then were at least 30% lower than in T3 SCI mice.
In T3 SCI mice, postinjury elevations of CORT and NE were associated with progressive splenic atrophy and leucopenia (Fig. 3). By 5 weeks postinjury, spleen volume and weight decreased 20–40% in all T3 SCI mice, a change due in part to marked loss of splenic white pulp (the region containing white blood cells; Fig. 3). Quantitative cytofluorimetric analyses revealed the breadth and magnitude of leukocyte depletion caused by T3 SCI (Fig. 4). Total numbers of splenic leukocytes decreased 50–70% between 3 and 5 weeks postinjury. All leukocyte subpopulations were affected by T3 SCI; however, B lymphocytes were the most severely depleted at both 21 and 35 dpi (Fig. 4). On average, spleens from T3 SCI mice had 9–15 million fewer splenic B cells than sham-injured or T9 SCI mice.

Splenic atrophy and B-cell loss could result from death of mature B cells (Lucin et al., 2007), impaired B-cell genesis (Oropallo et al., 2012), or both. To differentiate between these possibilities, mature B cells and B-cell progenitors were quantified (Fig. 5). Three and 5 weeks after T3 SCI, ~60% of mature B cells were lost, in part because of increased apoptosis (Figs. 4, 5A–D).

Two distinct subsets of mature B cells exist in the spleen—marginal zone and follicular B cells (Pillai and Cariappa, 2009). Marginal zone B cells form a first line of defense against circulating antigens, especially environmental pathogens, and readily develop into plasma (antibody-secreting) cells. Follicular B cells are the largest population of circulating B cells and are needed to generate memory B lymphocytes. After T3 SCI, a significant reduction in total mature B lymphocytes corresponded with significant reductions in both follicular and marginal zone B cells (Fig. 5B). T9 SCI had only a modest, nonsignificant effect on mature splenic B cells.

Loss of mature B cells is expected to stimulate compensatory lymphopoiesis, culminating in an increase in numbers of immature (transitional) B-cell progenitors (B220+/AA4.1−) (Woodland and Schmidt, 2005). Three weeks after T9 SCI, the numbers of splenic B-cell progenitors increased ~35–50% compared with sham-injured or T3 SCI mice (Fig. 5B). However, 2 weeks later (35 dpi), B-cell progenitor numbers returned toward baseline. Conversely, after T3 SCI there was a delayed loss of splenic B-cell progenitor cells; at 5 weeks postinjury numbers of splenic B-cell progenitors was reduced ~60% compared with sham-injured or T9 SCI mice (Fig. 5B).

The ability to produce antibodies against “non-self” proteins requires complex interactions between B and T cells. Because significantly fewer B and T cells populate the secondary lymphoid tissues of T3 SCI mice, especially at later times postinjury, when frequent episodes of AD are evident, we predicted that delayed immunizations would fail to elicit an immune response. Indeed, by 28 dpi, T3 SCI mice immunized with a non-self protein failed to generate significant antibody titers (Fig. 5E). T9 SCI mice produced normal concentrations of antibody after immunization (Fig. 5E).
Figure 7. Experimental (i.e., intentional) induction of AD exacerbates post-SCI splenic atrophy and immune suppression in rodents and humans. A–C, Colorectal distension and skin pinch cause AD and exacerbate splenic atrophy and leucopenia in T3 SCI mice. Successive bouts of AD were intentionally triggered using colorectal distension and cutaneous pinch (3 × each at 15, 16, and 17 dpi) and mice were killed at 21 dpi. A, Intentional induction of AD (iAD) caused marked loss of CD45R<sup>+</sup> splenic B lymphocytes. Scale bars, 1 mm. B, B-cell numbers were reduced >50% after iAD in T3 SCI mice. Only mild nonsignificant effects occurred in sham or T9 SCI mice. n = 3 mice/group, 3 sections/mouse; *p < 0.05; **p < 0.01; ***p < 0.001. C, Immunofluorescent staining of spleen (anti-CD45R, anti-CD3, and activated caspase-3 antibodies) shows that T- and B-cell apoptosis is increased by iAD in T3 SCI mice compared with iAD in sham or T9 SCI mice. White arrowheads delineate double-positive B cells. Scale bars: i–iii, 50 μm; iv, v, 10 μm. D, OVA-immunized T3 SCI mice with iAD produce significantly fewer anti-OVA antibodies than comparable sham control or T3 SCI mice. Serum anti-OVA IgG1 was measured at 28 dpi. n = 4–6/group; *p < 0.05; **p < 0.01. E, Micturition reflex triggered by abdominal tapping in a C5 neurologically complete SCI volunteer causes mild AD and is associated with exaggerated reflex catecholamine release and impaired immune function. Mean arterial pressure (MAP; 68–92 mm Hg), HR (52–60 bpm), plasma NE (51–350 pg/ml), and epinephrine (EPI; 7.5–29 pg/ml), in vitro proliferative lymphocyte responses to phytohemagglutinin (PHA) or pokeweed mitogen (PWM), and CD4:CD8 lymphocyte ratios were measured 15 min before voiding, immediately upon voiding (0), and 2, 5, 15, and 30 min after voiding.
AD-dependent immune suppression

High-level SCI causes AD that is associated temporally with immune suppression. Because there is currently no way to cure AD, it is difficult to prove a cause–effect relationship between AD and immune suppression. Therefore, we reasoned that if the cumulative effects of episodic AD are responsible for chronic splenic atrophy and immune suppression, then intentionally eliciting repeat bouts of AD at earlier times postinjury would recapitulate the effects of chronic spontaneous AD. To test this hypothesis, we used two techniques for eliciting AD, colorectal distension and skin pinch (Inskip et al., 2009). As shown in Figure 6, only in T3 SCI mice did these stimuli elicit hypertension with concurrent bradycardia (i.e., AD).

Because we did not want to introduce a potential immunosuppressive bias that might be associated with activation of visceral or somatic autonomic reflexes (but not the other), successive bouts of AD were experimentally triggered using both colorectal distension and skin pinch (Inskip et al., 2009). As shown in Figure 6, only in T3 SCI mice did these stimuli elicit hypertension with concurrent bradycardia (i.e., AD).

AD-dependent immune suppression

High-level SCI causes AD that is associated temporally with immune suppression. Because there is currently no way to cure AD, it is difficult to prove a cause–effect relationship between AD and immune suppression. Therefore, we reasoned that if the cumulative effects of episodic AD are responsible for chronic splenic atrophy and immune suppression, then intentionally eliciting repeat bouts of AD at earlier times postinjury would recapitulate the effects of chronic spontaneous AD. To test this hypothesis, we used two techniques for eliciting AD, colorectal distension and skin pinch (Inskip et al., 2009). As shown in Figure 6, only in T3 SCI mice did these stimuli elicit hypertension with concurrent bradycardia (i.e., AD).

Because we did not want to introduce a potential immunosuppressive bias that might be associated with activation of visceral or somatic autonomic reflexes (but not the other), successive bouts of AD were experimentally triggered using both colorectal distension and skin pinch. Between 21 and 35 dpi, T3 SCI mice normally experience episodes of AD daily, with the frequency increasing as a function of time postinjury (Fig. 1B). To mimic the effects of chronic spontaneously occurring episodic AD, SCI or sham-injured mice were exposed to sequential bouts of colorectal distension (3×) and then pinch (3×) each day for 3 d (n = 18 bouts of AD) beginning at 15 dpi. As shown in Figure 7, intentional activation of these AD-inducing spinal autonomic reflexes caused marked splenic white pulp atrophy and B-cell apoptosis after T3 SCI (Fig. 7A–C). Some loss of B cells occurred in the white pulp of all groups, presumably because eliciting spinal autonomic reflexes stimulates the release of immune modulatory GCs and NE. However, in both sham and T9 SCI groups, such hormonal changes were transient (Fig. 8) and a standardized immunization protocol elicited normal B-cell-dependent antibody production (Fig. 7D). In contrast, GCs remained high and splenic NE levels were increased in T3 SCI mice (Fig. 8). Also, the normally immune suppressive effects of T3 SCI were augmented by intentional induction of AD (Fig. 7D).

An independent clinical study, completed years before in a volunteer subject with chronic (>1 year) C5 SCI (AIS A) confirms the primary observations made in SCI mice. Specifically, eliciting a micturition reflex in this subject caused mild AD with a profound increase in circulating NE (baseline NE = 51 pg/ml increased to 162, 350, and 232 pg/ml, at 2, 5, and 15 min after voiding, respectively) and a decrease in circulating lymphocytes (Fig. 7E). Thirty minutes after voiding, the CD4:CD8 ratio, an
index of immune competence, was reduced ~25% and the ability to respond to mitogens was impaired relative to baseline (pre-micturition) function (Fig. 7E).

Reversing the immune suppressive effects of spontaneous AD after high-level SCI

The above data prove that eliciting spinal autonomic reflexes in spinalized mice causes AD and impairs immune function, presumably because immunomodulatory GCs and NE are released into the blood and immune organs with each dysreflexic episode. The cumulative effects of this neurogenic mechanism of immune suppression might be overcome by blocking GC and NE receptors. To test this hypothesis, selective $\beta_2$AR (butoxamine; 5 mg/kg) and GR antagonists (RU486; 5 mg/kg) were injected intraperitoneally daily at 1–7 dpi and 14–28 dpi. All mice were immunized at 18 dpi with OVA (100 $\mu$g) 1 h after injecting drugs. Spleen weight (normalized to body weight) (A) and OVA-specific antibodies (B) were analyzed in sera at 28 dpi. n = 4–6/group; *p < 0.05; **p < 0.01.

Discussion

Secondary immune deficiency is a serious but poorly understood medical complication after stroke or traumatic injury to the brain or spinal cord (Meisel et al., 2005). A consequence of posttraumatic immune suppression, referred to as CIDS, is recurrent or chronic infection. Infections impair neurological recovery and often are the cause of death several weeks or months after the primary insult (Meisel et al., 2005; Failli et al., 2012). This is especially true in tetraplegics, in whom immune dysfunction and infectious complications are more prevalent than in paraplegics (Meisel et al., 2005). Tetraplegics with injuries above the level of sympathetic outflow also are prone to developing AD. Novel data presented here implicate AD as a neurogenic mechanism capable of causing CIDS after SCI.

Using in vivo telemetry, we show here that mice with high-level SCI spontaneously develop recurring paroxysmal hypertension with bradycardia (i.e., AD). Because AD can occur without bradycardia, the current model likely under represents the true frequency of AD. Nevertheless, the temporal progression of AD in SCI mice mimics what has been described in humans. Specifically, AD spontaneously develops in two phases: early-onset AD develops during the first week postinjury, followed by a brief period of quiescence (Krassioukov et al., 2003). Depression of AD lasts only a few days, perhaps due to transient atrophy of spinal sympathetic preganglionic neurons (Krassioukov and Weaver, 1996). A second phase of stable and then enhanced AD develops over the ensuing weeks with the initial reemergence of AD evident by 2 weeks post-SCI. It is not entirely clear why it takes so long to reestablish AD; however, in rats, these functional changes correspond to evidence of anatomical sprouting and remodeling of spinal circuitry (e.g., sensory afferents and propriospinal axons; Cameron et al., 2006; Hou et al., 2008). Although a similarly detailed anatomical characterization of intraspinal plasticity has not yet been performed in SCI mice, the remarkable physiological similarities among SCI mice, rats, and humans makes the mouse a useful model for studying AD pathophysiology.

After high-level SCI, diverse stimuli, including distension of bladder or colon (Karlsson, 2006), cause reflex activation of SPNs and postganglionic noradrenergic fibers that innervate vasculature, viscera, lymphoid tissues, and the adrenal cortex. Circulating levels of NE also are controlled by SPNs that directly innervate the adrenal medulla. Our current data show that activation of this circuitry in SCI mice causes AD and is associated with an exaggerated reflex catecholamine response and immune suppression.

Previous work from us and others has shown that GCs and NE are released early after stroke, traumatic brain injury, or high-level SCI and cause splenic atrophy, leukocyte apoptosis, and immune suppression (Oberbeck et al., 2002; Prass et al., 2003; Offner et al., 2006; Lucin et al., 2007). However, because extracellular NE is metabolized within seconds to minutes, gross structural changes in spleen and immune suppression were considered as temporary adaptations to the acute injury (Mitchell et al., 1994). For example, organisms regulate blood volume distribution after severe trauma via splenic contraction (Hurford et al., 1996). Here, using serial in vivo MRI, we show that splenic atrophy is a dynamic but protracted process that is caused by recurrent activation of the same spinal autonomic reflexes that trigger AD. Within the atrophied spleen, accumulation of NE is likely a reflection of enhanced splenic nerve activity; however, a contribution from the adrenal medulla cannot be excluded (Kopin et al., 1978). Regardless of source, excess NE together with an increase in circulating GCs causes widespread apoptosis of inflammatory cells in the splenic white pulp (Lucin et al., 2009).

In humans with SCI, micturition is the most frequent AD-inducing stimulus, recurring ~3–6 h daily. Usually, the onset of AD is accompanied by symptoms including headache or sweating above the level of injury; however, AD also can be “silent” or
without symptoms. Silent AD is triggered by routine bowel and bladder care in susceptible patient populations (Linsenmeyer et al., 1996; Giannantoni et al., 1998; Kirshblum et al., 2002). Therefore, the overall frequency of AD is underappreciated, as is the potential for this aberrant reflex to modulate immune function. In a previous study, data from a human subject show that a single micrurition reflex causes AD with exaggerated catecholamine release and impaired immune function. At a minimum, these human data confirm the potential clinical relevance of our findings from the mouse SCI model.

B and T lymphocytes are especially sensitive to the effects of NE and GGS (Lucin et al., 2009). Activation and differentiation of naïve B cells occurs within specialized microdomains of secondary lymphoid tissues; there, B cells interact with T cells and dendritic cells to mount immune responses against virus and bacteria. Of paramount importance in this response is the production of antibodies. Antibodies bind a range of antigens including proteins, carbohydrates, and lipid moieties found on pathogens. Vaccines are designed to elicit B-cell activation and stimulate antibody production. We showed previously that splenic B-cell numbers are significantly reduced early after high-level SCI (Lucin et al., 2007). Oropallo et al. (2012) confirmed and extended those data showing that mature follicular, but not marginal zone B cells, are preferentially lost after SCI. Here, we show that both mature follicular and marginal zone B cells are lost and immature transitional B cell subsets (B220 \(^{+} /\text{AA4.1}^{+}\)) fail to repopulate the spleen after T3 SCI for up to 5 weeks post-injury. Lymphpocyte depletion of this magnitude would normally stimulate lymphopoiesis and migration of immature B cells from bone marrow.

AD is prevalent after high-level SCI, but it is not ubiquitous and not all who suffer from AD incur life-threatening infections or respond poorly to vaccines. Nevertheless, when AD develops, close monitoring of cardiovascular function might predict the onset of CIDS. For example, changes in HR variability can be easily measured using portable Holter monitors. In acute stroke patients, HR variability data can predict infectious complications (Günther et al., 2012). Similar analyses are feasible after SCI and can predict autonomic dysfunction (Inskip et al., 2012). Whether immune deficiency syndromes correlate with or can be predicted by HR variability after SCI requires additional research.

Overall, our present data provide a mechanism to explain why people with high-level SCI develop CIDS and clinically significant infectious complications. Specifically, we show that spontaneous uncontrolled activation of AD causes immune suppression, in part by releasing into the blood and immune organs high levels of immunomodulatory hormones that nonselectively kill mature and immature splenic leukocytes. Our data also show that optimal responses to vaccination can be achieved after high-level SCI by blocking activation of lymphocyte β1ARs and GRs. Other regimens of adrenoreceptor blockade have proven to be similarly effective in potentiating immune responses after stroke (Prass et al., 2003; Ajmo et al., 2009). Complementary mechanisms of immune suppression should be considered in the future, including studies designed to understand the effects of sustained SNS activation of invariant natural killer T cells in the liver or reflex activation of cholinergic anti-inflammatory T cells in the spleen (Rosas-Ballina et al., 2011; Wong et al., 2011). Both pathways are likely to be enhanced after high-level SCI and could represent therapeutic targets for reversing CIDS.

References


Mayorov DN, Adams MA, Krassioukov AV (2001) A Neurogenic Mechanism of Immune Suppression Caused by SCI.